Modality
Fusion Protein
MOA
CFTRmod
Target
PSMA
Pathway
T-cell
NarcolepsyRettEpilepsy
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Jun 2028
Phase 2Current
NCT06117533
642 pts·Epilepsy
2022-08→2028-06·Not yet recruiting
642 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-232.2y awayPh2 Data· Epilepsy
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2028-06-23 · 2.2y away
Epilepsy
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06117533 | Phase 2 | Epilepsy | Not yet recr... | 642 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| BGN-3859 | BeiGene | Approved | PSMA |